---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-129507"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T20:51:48.411235+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics regains Nasdaq compliance, hearing cancelled

## Summary
- Nasdaq confirmed Iterum cured its Listing Rule 5550(b) deficiency; previously scheduled Nov 21 hearing cancelled.
- Company will continue trading on Nasdaq Capital Market; avoids potential delisting.
- CEO Corey Fishman expressed commitment to adhere to listing requirements.

## SEC filing metadata
- accession: 0000950170-24-129507
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017024129507/0000950170-24-129507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017024129507/itrm-20241120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-129507
- JSON: https://secwatch.observer/filing/0000950170-24-129507.json
- Plain text: https://secwatch.observer/filing/0000950170-24-129507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.